Evidence / Yoshino M et al. · 2021

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Selected research. Study type, product relevance and limitations are shown separately.

Editorial study summary

Study type: Human randomized trial
Product relevance: Human ingredient research, specific to the population and outcomes studied.
Sample or population: 25 postmenopausal women with overweight/obesity and prediabetes
Studied dose: NMN 250 mg/day
Duration: 10 weeks
Finding: Researchers reported improved skeletal-muscle insulin sensitivity and insulin signalling in this specific study population.
Limitations: Small, selected population; NMN alone and a different dose. Not a diabetes-treatment claim, not a longevity endpoint, and not a trial of DR.MORGAN NMN 9600 PLUS.
Study quality: PubMed abstract and indexed metadata; detailed methods not fully reviewed
Funding and disclosures: NIH/NIA/NIDDK and other grants are listed in the PubMed record; complete conflict disclosure not assessed in the retrieved abstract.

This research does not establish results for a DR.MORGAN finished product.